LEADER 01364nam a2200301 u 4500
001 EB001840485
003 EBX01000000000000001004474
005 00000000000000.0
007 tu|||||||||||||||||||||
008 180702 r ||| eng
020 |a 9789283212669 
020 |a 9283212665 
245 0 0 |a Some pharmaceutical drugs  |h Elektronische Ressource 
260 |a Lyon, France  |b World Health Organization, International Agency for Research on Cancer  |c 1996, 1996 
300 |a iv, 514 p.  |b ill 
505 0 |a Includes bibliographical references and index 
653 |a Neoplasms / chemically induced 
653 |a Benzodiazepines / toxicity 
653 |a Estrogen Antagonists / toxicity 
653 |a Hypolipidemic Agents / toxicity 
710 2 |a IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 
710 2 |a International Agency for Research on Cancer 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a IARC monographs on the evaluation of carcinogenic risks to humans 
500 |a "This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic R6sks to Humans, which met in Lyon, 13-20 February 1996." 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK423860  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610